Measured Wealth Private Client Group’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $468K | Sell |
1,861
-281
| -13% | -$60.5K | 0.11% | 120 |
|
|
2026
Q1 | $466K | Sell |
2,142
-50
| -2% | -$11.1K | 0.13% | 112 |
|
|
2025
Q4 | $501K | Sell |
2,192
-151
| -6% | -$34.4K | 0.13% | 98 |
|
|
2025
Q3 | $542K | Sell |
2,343
-224
| -9% | -$45.6K | 0.15% | 96 |
|
|
2025
Q2 | $476K | Sell |
2,567
-15
| -0.6% | -$2.79K | 0.14% | 103 |
|
|
2025
Q1 | $541K | Sell |
2,582
-495
| -16% | -$96.2K | 0.17% | 82 |
|
|
2024
Q4 | $547K | Sell |
3,077
-172
| -5% | -$31.6K | 0.18% | 74 |
|
|
2024
Q3 | $642K | Sell |
3,249
-1,161
| -26% | -$217K | 0.21% | 64 |
|
|
2024
Q2 | $756K | Sell |
4,410
-133
| -3% | -$22K | 0.27% | 58 |
|
|
2024
Q1 | $827K | Buy |
4,543
+3
| +0.1% | +$517 | 0.29% | 50 |
|
|
2023
Q4 | $704K | Buy |
4,540
+4
| +0.1% | +$583 | 0.26% | 66 |
|
|
2023
Q3 | $676K | Sell |
4,536
-705
| -13% | -$103K | 0.27% | 59 |
|
|
2023
Q2 | $706K | Sell |
5,241
-1,289
| -20% | -$189K | 0.27% | 50 |
|
|
2023
Q1 | $1.04M | Buy |
6,530
+93
| +1% | +$14.2K | 0.4% | 37 |
|
|
2022
Q4 | $1.04M | Sell |
6,437
-76
| -1% | -$11.7K | 0.43% | 35 |
|
|
2022
Q3 | $874K | Sell |
6,513
-3,572
| -35% | -$513K | 0.39% | 37 |
|
|
2022
Q2 | $1.54M | Buy |
10,085
+2,075
| +26% | +$317K | 0.68% | 22 |
|
|
2022
Q1 | $1.3M | Sell |
8,010
-1,461
| -15% | -$212K | 0.48% | 27 |
|
|
2021
Q4 | $1.28M | Sell |
9,471
-1,214
| -11% | -$143K | 0.45% | 34 |
|
|
2021
Q3 | $1.15M | Buy |
10,685
+5,891
| +123% | +$673K | 0.44% | 35 |
|
|
2021
Q2 | $540K | Buy |
4,794
+943
| +24% | +$106K | 0.17% | 76 |
|
|
2021
Q1 | $417K | Buy |
3,851
+1,458
| +61% | +$156K | 0.15% | 77 |
|
|
2020
Q4 | $256K | Buy |
+2,393
| New | +$230K | 0.11% | 114 |
|
|
2020
Q3 | – | Sell |
-2,203
| Closed | -$216K | – | 136 |
|
|
2020
Q2 | $216K | Buy |
+2,203
| New | +$194K | 0.13% | 106 |
|
|
2019
Q3 | – | Sell |
-3,626
| Closed | -$264K | – | 135 |
|
|
2019
Q2 | $264K | Buy |
3,626
+276
| +8% | +$21.7K | 0.15% | 149 |
|
|
2019
Q1 | $270K | Sell |
3,350
-420
| -11% | -$34.4K | 0.17% | 136 |
|
|
2018
Q4 | $348K | Sell |
3,770
-116
| -3% | -$10.2K | 0.32% | 49 |
|
|
2018
Q3 | $367K | Sell |
3,886
-1,334
| -26% | -$127K | 0.22% | 81 |
|
|
2018
Q2 | $483K | Buy |
+5,220
| New | +$510K | 0.39% | 43 |
|
|
2017
Q3 | $264K | Buy |
+2,974
| New | +$226K | 0.36% | 38 |
|
Other funds holding ABBV
Measured Wealth Private Client Group's ABBV Position: Q2 2026 in Review
Measured Wealth Private Client Group reduced its AbbVie (ABBV) stake by 13% in Q2 2026, selling an estimated $60.5K and leaving 1,861 shares worth $468K. The position accounts for 0.11% of the portfolio, ranked #120.
Measured Wealth Private Client Group first reported a position in ABBV in Q3 2017 and has held it in 30 quarters since. The position peaked at $1.54M in Q2 2022. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Measured Wealth Private Client Group held 1,861 shares of AbbVie worth $468K as of Q2 2026.
- Measured Wealth Private Client Group sold 281 AbbVie shares in Q2 2026, an estimated $60.5K.
- AbbVie made up 0.11% of Measured Wealth Private Client Group's portfolio in Q2 2026, its #120 holding.
- Measured Wealth Private Client Group first reported a position in AbbVie in Q3 2017 and has held it in 30 quarters since.
- Measured Wealth Private Client Group's AbbVie position peaked at $1.54M in Q2 2022.
- 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Measured Wealth Private Client Group's 13F filing for Q2 2026, filed 10 Aug 2026.